CareDx and TC BioPharm Collaborate on ACHIEVE Clinical Trial
CareDx, Inc. (Nasdaq: CDNA) – the leader in precision medicine focused on transforming the healthcare experience for transplant patients – has announced an exciting collaboration with TC BioPharm. This partnership aims to use the cutting-edge AlloCell™ solution for pharmacokinetic analysis in the ACHIEVE clinical trial, designed to revolutionize treatment for those battling blood cancers.
Understanding the ACHIEVE Clinical Trial
The ACHIEVE clinical trial is noteworthy because it is an adaptive, open-label, Phase II study that is targeted towards measuring the efficacy and effectiveness of TCB008, an innovative allogeneic gamma-delta T-cell therapy. This trial specifically focuses on patients dealing with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS), aiming to open new frontiers in treatment options.
Significance of AlloCell in Clinical Trials
AlloCell has previously showcased its pivotal role in other clinical trials, with its application being utilized in ten prior cell therapy studies. Now, with involvement in the ACHIEVE trial, it is set to enhance its legacy by being part of four ongoing clinical trials. This evolution underlines the growing importance of AlloCell in the landscape of therapeutic solutions for serious health conditions.
Comments from Leadership
Marica Grskovic, PhD, CareDx Chief Strategy Officer, shared her enthusiasm: "This partnership builds upon our growth strategy to expand into hematology oncology with pharmacokinetic and monitoring assays for patients undergoing cell therapy. We are thrilled to continue to progress the science of allogeneic cell therapy for patients battling acute myeloid leukemia." Her statement captures the essence of progress that this partnership signifies.
A Pivotal Collaboration
Alison Bracchi, Executive Vice President of Clinical Operations at TC BioPharm expressed her excitement about the collaboration, noting, "Our partnership with CareDx is a significant milestone. The collaboration is pivotal to the development and optimization of TCB008 as a therapy for acute myeloid leukemia and other blood cancers." These sentiments encapsulate the importance of this alliance, reinforcing the shared commitment to advancing treatment methodologies.
Impact of AlloCell Technology
The AlloCell test, renowned for its sensitivity, plays a crucial role in pharmacokinetic monitoring of allogeneic immune and stem cell therapies, particularly in the context of the ACHIEVE trial. The data derived from the expansion and persistence of TCB008 in enrolled patients will shed light on the therapeutic potentials and immune system reconstitution in individuals diagnosed with AML. This understanding is crucial as it has the potential to significantly enhance patient care pathways.
About CareDx – Leading the Way in Transplant Healthcare
CareDx, Inc., headquartered in California, is at the forefront of precision medicine solutions. The company is dedicated to discovering, developing, and commercializing healthcare solutions that deliver high value for transplant patients and their caregivers. With a comprehensive range of testing services, products, and digital healthcare solutions, CareDx supports patients at every stage of their transplant journey, establishing itself as a trusted leader in genomic information for transplant recipients.
Frequently Asked Questions
What is the ACHIEVE clinical trial?
The ACHIEVE trial is an adaptive Phase II study evaluating TCB008, an allogeneic gamma-delta T-cell therapy, for patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
How does AlloCell assist in the ACHIEVE trial?
AlloCell aids in pharmacokinetic monitoring, providing vital data on the expansion and persistence of TCB008 in patients, which will enhance understanding of therapy efficacy.
What does the partnership signify for CareDx?
This collaboration signifies CareDx's strategic growth into hematology oncology, emphasizing innovative monitoring assays for cell therapy patients.
Who are the key players in this partnership?
Key players in this partnership include CareDx, led by Chief Strategy Officer Marica Grskovic, and TC BioPharm, represented by Executive VP Alison Bracchi.
What is CareDx's mission?
CareDx's mission is to deliver transformative healthcare solutions for transplant patients, ensuring high-value outcomes through innovative genomics-based services.
